Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors

Multiple Sclerosis Journal

Volumn 17, Issue 12, 2011, Pages 1472-1487

  Solomon, Andrew J ^a   Spain, Rebecca I ^b   Kruer, Michael C ^c   Bourdette, Dennis ^b  

^a FLETCHER ALLEN HEALTH CARE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF SOUTH DAKOTA   (United States)

Author keywords

antagonist; demyelination; inhibitor; multiple sclerosis; neuropathy; optic neuritis; tumor necrosis factor alpha

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BETA1A INTERFERON; BRAIN ANTIBODY; CALCIUM CHANNEL P TYPE; CALCIUM CHANNEL Q TYPE; CYCLOPHOSPHAMIDE; ETANERCEPT; GLATIRAMER; IMMUNOGLOBULIN; INFLIXIMAB; METHYLPREDNISOLONE; OLIGOCLONAL BAND; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VOLTAGE GATED CALCIUM CHANNEL;

ABDUCENS NERVE PARALYSIS; ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTHRITIS; ARTICLE; ATAXIA; AUTOIMMUNE LEUKOENCEPHALOPATHY; BULLOUS SKIN DISEASE; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL ARTICLE; CONSTIPATION; CROHN DISEASE; DRUG WITHDRAWAL; DYSARTHRIA; DYSESTHESIA; ENCEPHALITIS; ENTEROPATHIC ARTHRITIS; ENTEROPATHY; EYE MOVEMENT DISORDER; FEMALE; GRAVES DISEASE; HUMAN; INTERSTITIAL LUNG DISEASE; JUVENILE RHEUMATOID ARTHRITIS; LEUKOENCEPHALOPATHY; LIMB WEAKNESS; LIVEDO RETICULARIS; MALE; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; MYELITIS; NECROBIOSIS LIPOIDICA; NEURITIS; NEUROLOGIC DISEASE; NEUROMUSCULAR DISEASE; OPTIC NEURITIS; PARESTHESIA; PLASMAPHERESIS; POLYCRANIAL NEURITIS; POLYNEUROPATHY; POLYRADICULONEUROPATHY; PSEUDOBULBAR PALSY; PSORIASIS; PSORIATIC ARTHRITIS; RAYNAUD PHENOMENON; RHEUMATOID ARTHRITIS; RHOMBENCEPHALITIS; SCOTOMA; SMALL FIBER POLYNEUROPATHY; URINARY TRACT INFECTION; URINARY URGENCY; VISUAL IMPAIRMENT;

EID: 81755172594     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511412996     Document Type: Article

References (120)

1. Keystone EC, Ware CF. Tumor necrosis factor and anti-tumor necrosis factor therapies. J Rheumatol. 2010 ; 85 (Suppl). 27-39
2. Magnano MD, Robinson WH, Genovese MC. Demyelination and inhibition of tumor necrosis factor (TNF). Clin Exp Rheumatol. 2004 ; 22 (Suppl. 35). S134 - S140 (Pubitemid 39328366)
3. Robinson WH, Genovese MC, Moreland LW. Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?. Arthritis Rheum. 2001 ; 44: 1977-1983 (Pubitemid 33644038)
4. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology. 1999 ; 53: 457-465
5. Van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology. 1996 ; 47: 1531-1534 (Pubitemid 26422549)
6. Shin IS, Baer AN, Kwon HJ, Papadopoulos EJ, Siegel JN. Guillain-Barré and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy. Arthritis Rheum. 2006 ; 54: 1429-1434
7. Chan JW, Castellanos A. Infliximab and anterior optic neuropathy: case report and review of the literature. Graefes Arch Clin Exp Ophthalmol. 2010 ; 248: 283-287
8. Lozeron P, Denier C, Lacroix C, Adams D. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch Neurol. 2009 ; 66: 490-497
9. Tristano AG. Neurological adverse events associated with anti-tumor necrosis factor alpha treatment. J Neurol. 2010 ; 257: 1421-1431
10. Al Saieg N, Luzar MJ. Etanercept induced multiple sclerosis and transverse myelitis. J Rheumatol. 2006 ; 33: 1202-1204 (Pubitemid 43825482)
11. Bellesi M, Logullo F, Di Bella P, Provinciali L. CNS demyelination during anti-tumor necrosis factor alpha therapy. J Neurol. 2006 ; 253: 668-669 (Pubitemid 43877005)
12. Bensouda-Grimaldi L, Mulleman D, Valat JP, Autret-Leca E. Adalimumab-associated multiple sclerosis. J Rheumatol. 2007 ; 34: 239-240
13. Bidaguren A, Müller-Thyssen A, Blanco A, Mendicute J, Ubeda M. Retrobulbar optic neuritis associated with Infliximab. Arch Soc Esp Oftalmol. 2007 ; 82: 109-112
14. Cay HF, Gungor HA, Sezer I, Kacar C, Balci N. Adverse effect of TNF-alpha blocker? Demyelination in an ankylosing spondylitis patient: a case report. J Clin Pharm Ther. 2006 ; 31: 645-648 (Pubitemid 44813778)
15. Chung JH, Van Stavern GP, Frohman LP, Turbin RE. Adalimumab-associated optic neuritis. J Neurol Sci. 2006 ; 244: 133-136
16. Davis SA, Johnson RR, Pendleton JW. Demyelinating disease associated with use of etanercept in patients with seronegative spondyloarthropathies. J Rheumatol. 2008 ; 35: 1469-1470
17. Do HH, Mohamed A, Klistorner A, Grigg J. Ophthalmic manifestations of demyelination secondary to etanercept. Clin Exper Ophthalmol. 2008 ; 36: 392-394 (Pubitemid 352015187)
18. Enayati PJ, Papadakis KA. Association of anti-tumor necrosis factor therapy with the development of multiple sclerosis. J Clin Gastroenterol. 2005 ; 39: 303-306 (Pubitemid 40393245)
19. Freeman HJ, Flak B. Demyelination-like syndrome in Crohn's disease after infliximab therapy. Can J Gastroenterol. 2005 ; 19: 313-316 (Pubitemid 40812616)
20. Fromont A, De Seze J, Fleury MC, Maillefert JF, Moreau T. Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. Cytokine. 2009 ; 45: 55-57
21. Gomez-Gallego M, Meca-Lallana J, Fernandez-Barreiro A. Multiple sclerosis onset during etanercept treatment. Eur Neurol. 2008 ; 59: 91-93 (Pubitemid 350277270)
22. Jarand J, Zochodne DW, Martin LO, Voll C. Neurological complications of infliximab. J Rheumatol. 2006 ; 33: 1018-1020
23. Jarrett SJ, Cunnane G, Conaghan PG, et al. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol. 2003 ; 30: 2287-2291 (Pubitemid 37221866)
24. Kameda T, Dobashi H, Kittaka K, et al. A case of rheumatoid arthritis complicated by demyelination in both cerebral cortex and spinal cord during etanercept therapy. Mod Rheumatol. 2008 ; 18: 399-402
25. Kunzmann S, Warmuth-Metz M, Girschick HJ. Cerebral demyelination in association with TNF-inhibition therapy in a 5-year-old girl with aseptic meningitis as the first symptom of Still's disease. Scand J Rheumatol. 2005 ; 34: 76-78 (Pubitemid 40445067)
26. Kur-Zalewska J, Swarowska-Knap J, Tustochowicz W. Neurological disorders with demyelinating brain white matter lesions in a patient with rheumatoid arthritis treated with etanercept. Pol Arch Med Wewn. 2008 ; 118: 234-237 (Pubitemid 351613065)
27. Li SY, Birnbaum AD, Goldstein DA. Optic neuritis associated with adalimumab in the treatment of uveitis. Ocul Immunol Inflamm. 2010 ; 18: 475-481
28. Martínez-Taboada VM, Val-Bernal JF, Pesquera LC, et al. Demyelinating disease and cutaneous lymphocitic vasculitis after etanercept therapy in a patient with rheumatoid arthritis. Scand J Rheumatol. 2006 ; 35: 322-323 (Pubitemid 44181187)
29. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001 ; 44: 2862-2869 (Pubitemid 34016206)
30. Noguera-Pons R, Borrás-Blasco J, Romero-Crespo I, Antón-Torres R, Navarro-Ruiz A, González-Ferrandez JA. Optic neuritis with concurrent etanercept and isoniazid therapy. Ann Pharmacother. 2005 ; 39: 2131-2135 (Pubitemid 41745964)
31. Papadia M, Herbort CP. Infliximab-induced demyelination causes visual disturbance mistaken for recurrence of HLA-B27-related uveitis. Ocul Immunol Inflamm. 2010 ; 18: 482-484
32. Pfueller CF, Seipelt E, Zipp F, Paul F. Multiple sclerosis following etanercept treatment for ankylosing spondylitis. Scand J Rheumatol. 2008 ; 37: 397-399
33. Pikkel J. Possible link between infliximab and optic neuritis. Isr Med Assoc J. 2008 ; 10: 477-478
34. Ruiz-Jimeno T, Carvajal A, Mata C, Aurrecoechea E. Demyelinating disease in a patient with psoriatic arthritis and family history of multiple sclerosis treated with infliximab. J Rheumatol. 2006 ; 33: 1457-1458 (Pubitemid 44025170)
35. Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology. 2001 ; 57: 1885-1888 (Pubitemid 33096700)
36. Tanno M, Nakamura I, Kobayashi S, Kurihara K, Ito K. New-onset demyelination induced by infliximab therapy in two rheumatoid arthritis patients. Clin Rheumatol. 2006 ; 25: 929-933 (Pubitemid 44473174)
37. Thomas CW, Weinshenker BG, Sandborn WJ. Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease. Inflamm Bowel Dis. 2004 ; 10: 28-31 (Pubitemid 38072442)
38. Titelbaum DS, Degenhardt A, Kinkel RP. Anti-tumor necrosis factor alpha-associated multiple sclerosis. Am J Neuroradiol. 2005 ; 26: 1548-1550 (Pubitemid 43733459)
39. Vadikolias K, Kouklakis G, Heliopoulos I, et al. Acute paraplegia after the initiation of anti-tumour necrosis factor-alpha therapy for Crohn's disease. Eur J Gastroenterol Hepatol. 2007 ; 19: 159-162 (Pubitemid 46204334)
40. Van der Laken CJ, Lems WF, van Soesbergen RM, van der Sande JJ, Dijkmans BA. Paraplegia in a patient receiving anti-tumor necrosis factor therapy for rheumatoid arthritis: comment on the article by Mohan et al. Arthritis Rheum. 2003 ; 48: 269-270 (Pubitemid 36091674)
41. Winkelmann A, Patejdl R, Wagner S, Benecke R, Zettl UK. Cerebral MRI lesions and anti-tumor necrosis factor-alpha therapy. J Neurol. 2008 ; 255 (Suppl. 6). 109-114
42. Yamamoto M, Takahashi H, Wakasugi H, et al. Leukoencephalopathy during administration of etanercept for refractory rheumatoid arthritis. Mod Rheumatol. 2007 ; 17: 72-74 (Pubitemid 46758774)
43. Chang V, McCurdy D, Gordon LK. Etanercept associated optic neuropathy. Clin Experiment Ophthalmol. 2007 ; 35: 680-682 (Pubitemid 47491230)
44. Chung JH, van Stavern GP, Frohman LP, Turbin RE. Adalimumab-associated optic neuritis. J Neurol Sci. 2006 ; 244: 133-136
45. Foroozan R, Buono LM, Sergott RC, Savino PJ. Retrobulbar optic neuritis associated with infliximab. Arch Ophthalmol. 2002 ; 120: 985-987 (Pubitemid 34755558)
46. Hejazi R, Colombel JF, Peyrin-Biroulet L. Retrobulbar optic neuritis during infliximab treatment for ulcerative colitis. Gastroenterol Clin Biol. 2008 ; 32: 162-163 (Pubitemid 351625533)
47. Mejico LJ. Infliximab-associated retrobulbar optic neuritis. Arch Ophthalmol. 2004 ; 122: 793-794
48. Mumoli N, Niccoli G, Scazzeri F, Picchietti S, Greco A, Cei M. Infliximab-induced retrobulbar optic neuritis. QJM. 2007 ; 100: 531 (Pubitemid 47241920)
49. Ouakaa-Kchaou A, Gargouri D, Trojet S, et al. Retrobulbar optic neuritis associated with infliximab in a patient with Crohn's disease. J Crohns Colitis. 2009 ; 3: 131-133
50. Simsek I, Erdem H, Pay S, Sobaci G, Dinc A. Optic neuritis occurring with anti-tumour necrosis factor alpha therapy. Ann Rheum Dis. 2007 ; 6: 1255-1258 (Pubitemid 47309747)
51. Strong BY, Erny BC, Herzenberg H, Razzeca KJ. Retrobulbar optic neuritis associated with infliximab in a patient with Crohn's disease. Ann Intern Med. 2004 ; 140: W34
52. Tauber T, Daniel D, Barash J, Turetz J, Morad Y. Optic neuritis associated with etanercept therapy in two patients with extended oligoarticular juvenile idiopathic arthritis. Rheumatology (Oxford). 2005 ; 44: 405 (Pubitemid 40361305)
53. Ten Tusscher MP, Jacobs PJ, Busch MJ, de Graaf L, Diemont WL. Bilateral anterior toxic optic neuropathy and the use of infliximab. BMJ. 2003 ; 326: 579 (Pubitemid 36337585)
54. Tran TH, Milea D, Cassoux N, Bodaghi B, Bourgeois P, LeHoang P. Optic neuritis associated with infliximab. J Fr Ophtalmol. 2005 ; 28: 201-204 (Pubitemid 40343717)
55. Von Jagow B, Kohnen T. Anterior optic neuropathy associated with adalimumab. Ophthalmologica. 2008 ; 222: 292-294
56. Alexopoulou A, Koskinas J, Soultati A, et al. Acute bilateral phrenic neuropathy following treatment with adalimumab. Clin Rheumatol. 2009 ; 28: 1337-1340
57. Alshekhlee A, Basiri K, Miles JD, Ahmad SA, Katirji B. Chronic inflammatory demyelinating polyneuropathy associated with tumor necrosis factor-alpha antagonists. Muscle Nerve. 2010 ; 41: 723-727
58. Argyriou AA, Makridou A, Karanasios P, Makris N. Axonal common peroneal nerve palsy and delayed proximal motor radial conduction block following infliximab treatment. J Pain Symptom Manage. 2009 ; 38: e3 - e5
59. Barber CE, Lee P, Steinhart AH, Lazarou J. Multifocal motor neuropathy with conduction block following treatment with infliximab. J Rheumatol. 2010 ; 37: 1778-1780
60. Berthelot CN, George SJ, Hsu S. Distal lower extremity paresthesia and foot drop developing during adalimumab therapy. J Am Acad Dermatol. 2005 ; 53 (Suppl. 1). S260 - S262 (Pubitemid 41443484)
61. Bouchra A, Benbouazza K, Hajjaj-Hassouni N. Guillain-Barre in a patient with ankylosing spondylitis secondary to ulcerative colitis on infliximab therapy. Clin Rheumatol. 2009 ; 28 (Suppl. 1). S53 - S55
62. Burger DC, Florin TH. Peripheral neuropathy with infliximab therapy in inflammatory bowel disease. Inflamm Bowel Dis. 2009 ; 15: 1772
63. Carrilho PE, Araújo AC, Alves O, Kotze PG. Motor neuropathy with multiple conduction blocks associated with TNF-alpha antagonist. Arq Neuropsiquiatr. 2010 ; 68: 452-454
64. Cisternas M, Gutiérrez M, Jacobelli S. Successful rechallenge with anti-tumor necrosis factor alpha for psoriatic arthritis after development of demyelinating nervous system disease during initial treatment: comment on the article by Mohan et al. Arthritis Rheum. 2002 ; 46: 3107-3108
65. Cocito D, Bergamasco B, Tavella A, et al. Multifocal motor neuropathy during treatment with infliximab. J Peripher Nerv Syst. 2005 ; 10: 386-387
66. De Stefano R, Frati E, Volpi N, Galeazzi M. Sensory-motor axonal multineuropathy during etanercept therapy for rheumatoid arthritis. Clin Exp Rheumatol. 2009 ; 27: 381
67. Dubcenco E, Ottaway CA, Chen DL, Baker JP. Neurological symptoms suggestive of demyelination in Crohn's disease after infliximab therapy. Eur J Gastroenterol Hepatol. 2006 ; 18: 565-566 (Pubitemid 43832762)
68. Eguren C, Díaz Ley B, Daudén E, García-Diez A, Losada M. Peripheral neuropathy in two patients with psoriasis in treatment with infliximab. Muscle Nerve. 2009 ; 40: 488-489
69. Faivre A, Franques J, De Paula AM, et al. Acute motor and sensory axonal neuropathy and concomitant encephalopathy during tumor necrosis factor-alpha antagonist therapy. J Neurol Sci. 2010 ; 291: 103-106
70. Fee DB, Kasarskis EJ. Myasthenia gravis associated with etanercept therapy. Muscle Nerve. 2009 ; 39: 866-870
71. Galassi G, Ariatti A, Codeluppi L, Meletti S. Comment on myasthenia gravis associated with TNF-alpha receptor blockers: A multifaceted issue. Muscle Nerve. 2010 ; 42: 296-298
72. Hall HA, Zimmermann B. Evolution of dermatomyositis during therapy with a tumor necrosis factor alpha inhibitor. Arthritis Rheum. 2006 ; 55: 982-984 (Pubitemid 44917476)
73. Hanaoka BY, Libecco J, Rensel M, Hajj-Ali RA. Peripheral mononeuropathy with etanercept use: case report. J Rheumatol. 2008 ; 35: 182
74. Hooper DR, Tarnopolsky MA, Baker SK. Lewis-Sumner syndrome associated with infliximab therapy in rheumatoid arthritis. Muscle Nerve. 2008 ; 38: 1318-1325
75. Ishikawa Y, Yukawa N, Ohmura K, et al. Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature. Clin Rheumatol. 2010 ; 29: 563-566
76. Kelly S, Connolly S, McCarthy A, Hutchinson M, Murphy S, Turbridy N. PONM12. Multifocal motor neuropathy due to infliximab. J Neurol Neurosurg Psychiatry. 2010 ; 81: e63
77. Kiltz U, Fendler C, Braun J. Neuromuscular involvement in rheumatic patients treated with anti-tumor necrosis factor therapy-three examples. J Rheumatol. 2008 ; 35: 2074-2076
78. Klein R, Rosenbach M, Kim EJ, Kim B, Werth VP, Dunham J. Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol. 2010 ; 146: 780-784
79. Kurmann PT, van Linthoudt D, So AK. Miller-Fisher syndrome in a patient with rheumatoid arthritis treated with adalimumab. Clin Rheumatol. 2009 ; 28: 93-94
80. Makol A, Grover M. Adalimumab induced mononeuritis multiplex in a patient with refractory 93.rheumatoid arthritis: a case report. Cases J. 2008 ; 1: 287
81. Musia J, Undas A, Celińska-Lowenhoff M. Polymyositis associated with infliximab treatment for rheumatoid arthritis. Rheumatology (Oxford). 2003 ; 42: 1566-1568 (Pubitemid 37508935)
82. Nancey S, Bouhour F, Boschetti G, et al. Lewis and Sumner syndrome following infliximab treatment in Crohn's disease: a report of 2 cases. Inflamm Bowel Dis. 2010 ; 16: 1450-1453
83. Paolazzi G, Peccatori S, Cavatorta FP, Morini A. A case of spontaneously recovering multifocal motor neuropathy with conduction blocks (MMNCB) during anti-TNF alpha therapy for ankylosing spondylitis. Clin Rheumatol. 2009 ; 28: 993-995
84. Richette P, Dieudé P, Damiano J, Lioté F, Orcel P, Bardin T. Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis. J Rheumatol. 2004 ; 31: 2079-2081 (Pubitemid 39336740)
85. Richez C, Blanco P, Lagueny A, Schaeverbeke T, Dehais J. Neuropathy resembling CIDP in patients receiving tumor necrosis factor-alpha blockers. Neurology. 2005 ; 64: 1468-1470 (Pubitemid 40570527)
86. Rodriguez-Escalera C, Belzunegui J, Lopez-Dominguez L, Gonzalez C, Figueroa M. Multifocal motor neuropathy with conduction block in a patient with rheumatoid arthritis on infliximab therapy. Rheumatology (Oxford). 2005 ; 44: 132-133 (Pubitemid 40124349)
87. Silburn S, McIvor E, McEntegart A, Wilson H. Guillain-Barré syndrome in a patient receiving anti-tumour necrosis factor alpha for rheumatoid arthritis: a case report and discussion of literature. Ann Rheum Dis. 2008 ; 67: 575-576 (Pubitemid 351498447)
88. Singer OC, Otto B, Steinmetz H, Ziemann U. Acute neuropathy with multiple conduction blocks after TNFalpha monoclonal antibody therapy. Neurology. 2004 ; 63: 1754 (Pubitemid 39507613)
89. Tektonidou MG, Serelis J, Skopouli FN. Peripheral neuropathy in two patients with rheumatoid arthritis receiving infliximab treatment. Clin Rheumatol. 2007 ; 26: 258-260 (Pubitemid 46020257)
90. Urata Y, Wakai Y, Kowatari K, Nitobe T, Mizushima Y. Polymyositis associated with infliximab treatment for rheumatoid arthritis. Mod Rheumatol. 2006 ; 16: 410-411 (Pubitemid 44921592)
91. Fardet L, Dupuy A, Kerob D, et al. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol. 2007 ; 56: 624-628 (Pubitemid 46400174)
92. Felekis T, Katsanos K, Christodoulou D, Asproudis I, Tsianos EV. Reversible bilateral optic neuritis after Infliximab discontinuation in a patient with Crohn's disease. J Crohns Colitis. 2009 ; 3: 212-214
93. Hamon MA, Nicolas G, Deviere F, Letournel F, Dubas F. Demyelinating neuropathy during anti-TNF alpha treatment with a review of the literature. Rev Neurol. 2007 ; 163: 1232-1235
94. Lees CW, Ali AI, Thompson AI, et al. The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. Aliment Pharmacol Ther. 2009 ; 29: 286-297
95. Munteis-Olivas E, Pérez-García C, Roquer-González J, Maymo-Guarch J. Multiple sclerosis after treatment with anti-TNF-alpha antibodies. Med Clin (Barc). 2005 ; 125: 759 (Pubitemid 43010331)
96. Rebolleda G. Optic neuritis and infliximab. Arch Soc Esp Oftalmol. 2004 ; 79: 591
97. Saint Marcoux B, de Bandt M. Vasculitides induced by TNFalpha antagonists: A study in 39 patients in France. Joint Bone Spine. 2006 ; 73: 710-713 (Pubitemid 44918417)
98. Sillero Sánchez M, García Domínguez G, Asencio Marchante JJ. Demyelinating encephalomyelitis associated with treatment with adalimumab. Neurologia. 2010 ; 25: 136-138
99. Sukal SA, Nadiminti L, Granstein RD. Etanercept and demyelinating disease in a patient with psoriasis. J Am Acad Dermatol. 2006 ; 54: 160-164 (Pubitemid 41832480)
100. Bernatsky S, Renoux C, Suissa S. Demyelinating events in rheumatoid arthritis after drug exposures. Ann Rheum Dis. 2010 ; 69: 1691-1693
101. Kumar D, Bouldin TW, Berger RG. A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab. Arthritis Rheum. 2010 ; 62: 3191-3195
102. Kastrup O, Diener HC. TNF-antagonist etanercept induced reversible posterior leukoencephalopathy syndrome. J Neurol. 2008 ; 255: 452-453
103. Cohen R, Robinson D, Paramore C, Fraeman K, Renahan K, Bala M. Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001-2002. Inflamm Bowel Dis. 2008 ; 14: 738-743 (Pubitemid 351898056)
104. Midgard R, Grønning M, Riise T, Kvåle G, Nyland H. Multiple sclerosis and chronic inflammatory diseases. A case-control study. Acta Neurol Scand. 1996 ; 93: 322-328 (Pubitemid 26201460)
105. Nielsen NM, Frisch M, Rostgaard K, et al. Autoimmune diseases in patients with multiple sclerosis and their first-degree relatives: a nationwide cohort study in Denmark. Mult Scler. 2008 ; 14: 823-829
106. Ramagopalan SV, Dyment DA, Valdar W, et al. Autoimmune disease in families with multiple sclerosis: a population-based study. Lancet Neurol. 2007 ; 6: 604-610 (Pubitemid 46921044)
107. Ascherio A, Munger K. Epidemiology of multiple sclerosis: from risk factors to prevention. Semin Neurol. 2008 ; 28: 17-28 (Pubitemid 351273081)
108. Pan W, Kastin AJ. Tumor necrosis factor and stroke: role of the blood-brain barrier. Prog Neurobiol. 2007 ; 83: 363-374 (Pubitemid 350116341)
109. Watanabe Y, Morita M, Ikematsu N, Akaike T. Tumor necrosis factor alpha and interleukin-1 beta but not interferon gamma induce vascular cell adhesion molecule-1 expression on primary cultured murine hepatocytes. Biochem Biophys Res Commun. 1995 ; 209: 335-342
110. Diehl AM, Rai R. Regulation of liver regeneration by pro-inflammatory cytokines. J Gastroenterol Hepatol. 1996 ; 11: 466-470 (Pubitemid 26151922)
111. Van Herreweghe F, Festjens N, Declercq W, Vandenabeele P. Tumor necrosis factor-mediated cell death: to break or to burst, that's the question. Cell Mol Life Sci. 2010 ; 67: 1567-1579
112. Beattie MS, Hermann GE, Rogers RC, Bresnahan JC. Cell death in models of spinal cord injury. Prog Brain Res. 2002 ; 137: 37-47 (Pubitemid 35460935)
113. Klinkert WE, Kojima K, Lesslauer W, Rinner W, Lassmann H, Wekerle H. TNF-alpha receptor fusion protein prevents experimental auto-immune encephalomyelitis and demyelination in Lewis rats: an overview. J Neuroimmunol. 1997 ; 72: 163-168 (Pubitemid 27062772)
114. Arnett HA, Mason J, Marino M, Suzuki K, Matsushima GK, Ting JP. TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci. 2001 ; 4: 1116-1122 (Pubitemid 34116557)
115. Taoufik E, Tseveleki V, Euagelidou M, et al. Positive and negative implications of tumor necrosis factor neutralization for the pathogenesis of multiple sclerosis. Neurodegener Dis. 2008 ; 5: 32-37 (Pubitemid 350261814)
116. Williams EL, Gadola S, Edwards CJ. Anti-TNF-induced lupus. Rheumatology (Oxford). 2009 ; 48: 716-720
117. Alessandri C, Scrivo R, Spinelli FR, et al. Autoantibody production in anti-TNF-alpha-treated patients. Ann N Y Acad Sci. 2007 ; 1110: 319-329
118. Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. 2000 ; 43: 2383-2390
119. Blanco P, Palucka AK, Pascual V, Banchereau J. Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev. 2008 ; 19: 41-52
120. Jewett A, Bonavida B. Activation of the human immature natural killer cell subset by IL-12 and its regulation by endogenous TNF-alpha and IFN-gamma secretion. Cell Immunol. 1994 ; 154: 273-286 (Pubitemid 24115132)